![](https://monteverdelaw.com/wp-content/uploads/case-logo/magenta-therapeutics-inc.jpg)
Magenta Therapeutics, Inc. (NASDAQ: MGTA), relating to its proposed merger with Dianthus Therapeutics, Inc. Under the terms of the agreement, MGTA shareholders are expected to own approximately 21.3% of the combined company
Magenta Therapeutics, Inc. (NASDAQ: MGTA), relating to its proposed merger with Dianthus Therapeutics, Inc. Under the terms of the agreement, MGTA shareholders are expected to own approximately 21.3% of the combined company